STEpwise Research Program to Promote INGeniouS ONline Supportive Solutions in the Relief of Cancer-related Fatigue

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorGustave Roussy, Cancer Campus, Grand Paris

About this trial

Decentralized, randomized hybrid type 2 (effectiveness/implementation) controlled trial comparing the effectiveness of three different digital aid modalities programs in reducing the perceived burden of CRF in cancer patients while also gathering data on the implementation strategy.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18 years and older.

Having a clinical diagnosis of cancer including patients on active treatment or cancer survivors.

Self-reporting moderate to severe CRF for at least one week (worst level of fatigue ≥ 4 on a 10-point numerical rating scale, retained in international guidelines as an optimal cutoff for identifying clinically significant CRF).

Being able to read and understand French.

Disqualifiers

Suffering from current psychiatric disorder or cognitive disorder that would interfere with the ability to consent or participate.

Currently engaging in cognitive-behavioral therapy.

Currently engaging in another non-drug (behavioral) clinical trial.

Suffering from physical related reversible and treatable causes of fatigue (anemia, electrolytes unbalance, infections, renal dysfunction, active metastases causing fatigue, hormonal unbalances (hypothyroidism, adrenal insufficiency, etc.) - according to physician's judgement at the moment of inclusion.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Educational content

    Device

    Patients will have access to educational content on the mobile app Resilience © in the format of articles, videos or podcasts on treatment related symptoms and on validated supportive care interventions. This version is currently public available in France and Belgium at www.resilience.care and is considered the control group (education only).

  • Educational material plus self-management program - self-administered version

    Device

    Patients will have access to the same mobile app (Resilience ©) with its educational content will be powered with a self-guided fatigue self-management program based on a cognitive behavioral therapy approach.

  • Educational material plus self-management program - guided version with mental health professional

    Device

    Patients will have access to the same mobile app (Resilience ©) with its educational content and the self-management program of arm 2 and weekly calls with a certified mental health professional certified in cognitive behavioural therapy for guided coaching across the self-management program.

Treatment groups

372 Participants
are divided into 3 treatment groups
Group A: Educational material aid toolSham comparator 1 intervention
Group B: Educational material plus self-management program - self-administered versionExperimental treatment 1 intervention
Group C: Educational material plus self-management program - guided version with mental health professionalExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Compare the effectiveness of standard of care plus three different types of digital aid modalities for the patient.

Compare the effectiveness of standard of care (provided by the patient's cancer center and their treating oncologist) plus three different types of digital aid modalities for the patient (1: educational material; 2: educational material plus self-management program based on a cognitive behavioural therapy strategy - self-administered; 3: educational material plus self-management program based on a cognitive behavioural therapy strategy - guided by a psychologist) in reducing the perceived burden of CRF (cancer-related fatigue), measured as a clinically meaningful change (≥ 6 points) in fatigue scores in the fatigue subscale of the EORTC QLQ C30 questionnaire from baseline to short-term assessments.

Time frame
3 months and 6 months after the end of the program.

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Gustave Roussy, Cancer Campus, Grand Paris

Lead sponsor

University Hospital, Bordeaux

Collaborator

Institut Bergonié

Collaborator